Physician profile
Patrick R Volak
NPI 1174518336
$12,765.12
in general payments reported to CMS, 2019-2025
40 companies · $2,886 in 2025
The $2,886 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,215 · 2020: $579 · 2021: $1,364 · 2022: $2,529 · 2023: $2,030 · 2024: $2,163 · 2025: $2,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,996 · Education: $82.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,995.88 |
| Education | $82.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,303.86 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,356.04 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,243.40 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $914.46 | 2019-2025 | Tremfya, Stelara, Remicade |
| Pfizer INC. | $754.71 | 2019-2025 | |
| Echosens North America, INC. | $559.32 | 2022 | |
| Gilead Sciences, INC. | $531.53 | 2019-2025 | |
| Celgene Corporation | $448.18 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $401.50 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $369.26 | 2022-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $349.69 | 2019-2024 | Rebyota |
| Olympus America INC. | $269.45 | 2019-2021 | |
| Daiichi Sankyo INC. | $243.44 | 2019-2025 | Injectafer |
| Phathom Pharmaceuticals, INC. | $227.15 | 2024-2025 | Voquezna |
| Genzyme Corporation | $225.45 | 2022-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $216.79 | 2019-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $171.40 | 2021-2024 | Dificid |
| Aimmune Therapeutics, INC. | $108.75 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $107.19 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $99.97 | 2023-2025 | Yuflyma, Zymfentra, Vegzelma |
| Ironwood Pharmaceuticals, INC | $92.15 | 2019-2024 | Linzess |
| Medtronic, INC. | $82.97 | 2022-2025 | Interstim |
| Ipsen Biopharmaceuticals, INC | $82.03 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $73.33 | 2024-2025 | Resmetirom, Rezdiffra |
| Braintree Laboratories, INC. | $71.99 | 2021-2023 | Sutab |
| Intercept Pharmaceuticals, INC. | $69.47 | 2019-2024 | Ocaliva |
| Ucb, INC. | $62.60 | 2019-2020 | |
| Biocon Biologics INC | $62.01 | 2025 | Yesintek |
| Nestle Healthcare Nutrition INC. | $58.26 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $34.80 | 2023 | Zeposia |
| Allergan, INC. | $29.23 | 2019 | |
| Alnylam Pharmaceuticals INC. | $28.32 | 2022 | |
| Alkermes, INC. | $22.23 | 2021 | |
| Redhill Biopharma INC. | $19.47 | 2020 | |
| Sanofi-Aventis U.S. LLC | $17.13 | 2025 | |
| Organon LLC | $16.86 | 2023 | Hadlima |
| Novo Nordisk INC | $14.43 | 2025 | Wegovy |
| Recordati_rare_diseases_inc. | $13.53 | 2023 | Panhematin |
| Amgen INC. | $12.77 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,097.44 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Volak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.